Literature DB >> 17251295

Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor.

Simon Cocklin1, Hosahudya Gopi, Bianca Querido, Manideepthi Nimmagadda, Syna Kuriakose, Claudia Cicala, Sandya Ajith, Sabine Baxter, James Arthos, Julio Martín-García, Irwin M Chaiken.   

Abstract

The AIDS epidemic continues to spread at an alarming rate worldwide, especially in developing countries. One approach to solving this problem is the generation of anti-human immunodeficiency virus (HIV) compounds with inhibition spectra broad enough to include globally prevailing forms of the virus. We have examined the HIV type 1 (HIV-1) envelope specificity of a recently identified entry inhibitor candidate, HNG-105, using surface plasmon resonance spectroscopy and pseudovirus inhibition assays. The combined results suggest that the HNG-105 molecule may be effective across the HIV-1 subtypes, and they highlight its potential as a lead for developing therapeutic and microbicidal agents to help combat the spread of AIDS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17251295      PMCID: PMC1866025          DOI: 10.1128/JVI.01778-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

Review 1.  Inhibiting HIV-1 entry with fusion inhibitors.

Authors:  C E Baldwin; R W Sanders; B Berkhout
Journal:  Curr Med Chem       Date:  2003-09       Impact factor: 4.530

Review 2.  HIV-1 entry and its inhibition.

Authors:  T C Pierson; R W Doms
Journal:  Curr Top Microbiol Immunol       Date:  2003       Impact factor: 4.291

Review 3.  HIV-1 entry inhibitors: closing the front door.

Authors:  Brian Tomkowicz; Ronald G Collman
Journal:  Expert Opin Ther Targets       Date:  2004-04       Impact factor: 6.902

4.  Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.

Authors:  Alyssa C Biorn; Simon Cocklin; Navid Madani; Zhihai Si; Tijana Ivanovic; James Samanen; Donald I Van Ryk; Ralph Pantophlet; Dennis R Burton; Ernesto Freire; Joseph Sodroski; Irwin M Chaiken
Journal:  Biochemistry       Date:  2004-02-24       Impact factor: 3.162

5.  Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.

Authors:  J P Moore; F E McCutchan; S W Poon; J Mascola; J Liu; Y Cao; D D Ho
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  Infection of primary human microglia and monocyte-derived macrophages with human immunodeficiency virus type 1 isolates: evidence of differential tropism.

Authors:  J M Strizki; A V Albright; H Sheng; M O'Connor; L Perrin; F González-Scarano
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 7.  HIV-1 entry and reverse transcription in macrophages.

Authors:  W A O'Brien
Journal:  J Leukoc Biol       Date:  1994-09       Impact factor: 4.962

Review 8.  Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.

Authors:  Horatio B Fung; Yi Guo
Journal:  Clin Ther       Date:  2004-03       Impact factor: 3.393

Review 9.  Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention.

Authors:  Ingrid Markovic; Kathleen A Clouse
Journal:  Curr HIV Res       Date:  2004-07       Impact factor: 1.581

10.  Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14.

Authors:  S Dewhurst; J E Embretson; D C Anderson; J I Mullins; P N Fultz
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

View more
  21 in total

1.  Exploring Modifications of an HIV-1 Capsid Inhibitor: Design, Synthesis, and Mechanism of Action.

Authors:  Jimmy P Xu; Ashwanth C Francis; Megan E Meuser; Marie Mankowski; Roger G Ptak; Adel A Rashad; Gregory B Melikyan; Simon Cocklin
Journal:  J Drug Des Res       Date:  2018-08-13

2.  Large-scale conformational sampling of proteins using temperature-accelerated molecular dynamics.

Authors:  Cameron F Abrams; Eric Vanden-Eijnden
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

3.  The active core in a triazole peptide dual-site antagonist of HIV-1 gp120.

Authors:  Muddegowda Umashankara; Karyn McFadden; Isaac Zentner; Arne Schön; Srivats Rajagopal; Ferit Tuzer; Syna A Kuriakose; Mark Contarino; Judith Lalonde; Ernesto Freire; Irwin Chaiken
Journal:  ChemMedChem       Date:  2010-11-08       Impact factor: 3.466

4.  Lytic Inactivation of Human Immunodeficiency Virus by Dual Engagement of gp120 and gp41 Domains in the Virus Env Protein Trimer.

Authors:  Bibek Parajuli; Kriti Acharya; Reina Yu; Brendon Ngo; Adel A Rashad; Cameron F Abrams; Irwin M Chaiken
Journal:  Biochemistry       Date:  2016-10-27       Impact factor: 3.162

5.  Non-natural peptide triazole antagonists of HIV-1 envelope gp120.

Authors:  Kantharaju Kamanna; Rachna Aneja; Caitlin Duffy; Pamela Kubinski; Diogo Rodrigo Moreira; Lauren D Bailey; Karyn McFadden; Arne Schön; Andrew Holmes; Ferit Tuzer; Mark Contarino; Ernesto Freire; Irwin M Chaiken
Journal:  ChemMedChem       Date:  2012-12-13       Impact factor: 3.466

6.  Cell-free HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120.

Authors:  Arangassery R Bastian; Karyn McFadden; Caitlin Duffy; Srivats Rajagopal; Mark R Contarino; Elisabeth Papazoglou; Irwin Chaiken
Journal:  ChemMedChem       Date:  2011-06-28       Impact factor: 3.466

7.  Chimeric Cyanovirin-MPER recombinantly engineered proteins cause cell-free virolysis of HIV-1.

Authors:  Mark Contarino; Arangassery R Bastian; Ramalingam Venkat Kalyana Sundaram; Karyn McFadden; Caitlin Duffy; Vamshi Gangupomu; Michelle Baker; Cameron Abrams; Irwin Chaiken
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

8.  A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption.

Authors:  Ali Emileh; Ferit Tuzer; Herman Yeh; Muddegowda Umashankara; Diogo R M Moreira; Judith M Lalonde; Carole A Bewley; Cameron F Abrams; Irwin M Chaiken
Journal:  Biochemistry       Date:  2013-03-22       Impact factor: 3.162

9.  Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.

Authors:  Hosahudya Gopi; M Umashankara; Vanessa Pirrone; Judith LaLonde; Navid Madani; Ferit Tuzer; Sabine Baxter; Isaac Zentner; Simon Cocklin; Navneet Jawanda; Shendra R Miller; Arne Schön; Jeffrey C Klein; Ernesto Freire; Fred C Krebs; Amos B Smith; Joseph Sodroski; Irwin Chaiken
Journal:  J Med Chem       Date:  2008-04-11       Impact factor: 7.446

10.  Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120.

Authors:  Hosahudya Gopi; Simon Cocklin; Vanessa Pirrone; Karyn McFadden; Ferit Tuzer; Isaac Zentner; Sandya Ajith; Sabine Baxter; Navneet Jawanda; Fred C Krebs; Irwin M Chaiken
Journal:  J Mol Recognit       Date:  2009 Mar-Apr       Impact factor: 2.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.